Intranasal lidocaine 8% spray for second-division trigeminal neuralgia

Kanai, Akifumi; Suzuki, Asaha; Kobayashi, Miyuki; Hoka, Sumio

doi:10.1093/bja/ael180

Cited by 95 publications

(83 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A loading dose of 14 mg/kg applied intravenously was required to relieve the pain for 12 days, which is long enough for alternative oral drug therapy to kick in when initiated simultaneously [Cheshire, 2001]. Intranasal administered lidocaine 8% was effective in temporarily relieving second-division neuralgic pain [Kanai et al 2006b]. Subcutaneous sumatriptan 3 mg was shown to be superior to placebo in providing prompt and marked analgesia in 80% of patients in a double-blind, placebo-controlled study of 24 patients with refractory TN.…”

Section: Acute Neuralgia Attack Treatmentmentioning

confidence: 99%

Treatment options in trigeminal neuralgia

Obermann

2010

Ther Adv Neurol Disord

175

133

View full text Add to dashboard Cite

The incidence of trigeminal neuralgia (TN) is 4.3 per 100,000 persons per year, with a slightly higher incidence for women (5.9/100,000) compared with men (3.4/100,000). There is a lack of certainty regarding the aetiology and pathophysiology of TN. The treatment of TN can be very challenging despite the numerous options patients and physicians can choose from. This multitude of treatment options poses the question as to which treatment fits which patient best. The preferred medical treatment for TN consists of anticonvulsant drugs, muscle relaxants and neuroleptic agents. Large-scale placebo-controlled clinical trials are scarce. For patients refractory to medical therapy, Gasserian ganglion percutaneous techniques, gamma knife surgery and microvascular decompression are the most promising invasive treatment options.

show abstract

Section: Acute Neuralgia Attack Treatmentmentioning

confidence: 99%

Treatment options in trigeminal neuralgia

Obermann

2010

Ther Adv Neurol Disord

175

133

View full text Add to dashboard Cite

show abstract

“…Единичные оптимистичные сооб-щения о том, что МРТ позволяет по особенностям конфликта выби-рать метод лечения и прогнозировать возможные рецидивы заболе-вания [125,261] меркнут на фоне значительного количества работ, ставящих под сомнение васкулоневральный конфликт как патоге-нетическую основу заболевания. Так, Kress B, et al (2006) у 73% доб-ровольцев, не страдавших НТН, обнаружили контакт между КТН и смежными сосудами: в 61% это была артерия и в 39% -вена.…”

Section: значение спиральной компьютерной ангиографии в диагностике вunclassified

“…118). С целью выключения триггерных зон, в особенности при НТН с локализацией болей в области второй ветви, некоторые авторы ис-пользуют лидокаиновый интранозальный спрей [261].…”

Section: таблица 44unclassified

Классическая Невралгия Тройничного Нерва

Балязина¹

2015

View full text Add to dashboard Cite

“…Kanai et al 25 examined the effectiveness of intranasal lidocaine 8% spray on paroxysmal pain in second-division trigeminal neuralgia in a randomized and open-label study. After 7 days intranasal lidocaine 8% spray significantly decreased VAS, whereas the placebo spray did not.…”

Section: Lidocainementioning

confidence: 99%

Promising treatments for neuropathic pain

Schestatsky

Vidor

Winckler

et al. 2014

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

In the last few years the understanding of mechanisms and, consequently, the diagnosis of neuropathic pain (NP) has becoming progressively clearer in clinical practice. However, the treatment of such condition remains challenging so far. One of the reasons for such difficulty is the diversity of mechanisms involved in NP generation and its persistency. In the present review we discuss several treatment modalities for NP that are scantily applied in daily clinical practice. For that, we collected positive clinical evidence of unusual and SECS (Safe, Easy, Cheap, and Sensible) approaches for NP. The aim of this review is not to establish the "state of the art" or rigid guidelines for NP treatment. In a different way, we only want bring new possibilities of treatment to the readers and also to motivate investigators to confirm those positive preliminary but promising results for NP reliev.Keywords: neuropathic pain, treatment, unconventional, alternative, evidence-based medicine. RESUMONos últimos anos, a compreensão dos mecanismos e consequentemente do diagnóstico da dor neuropática (DN) têm se tornado cada vez mais claros na prática clínica. Entretanto, o tratamento desta condição continua sendo um desafio. Uma das razões para tal dificuldade é diversidade de mecanismos envolvidos na geração e perpetuação da DN. Na presente revisão, os autores discutem várias modalidades de tratamento para DN pouco utilizadas na prática clínica diária. Para isso, selecionamos evidências clínicas positivas de abordagens para DN consideradas não-convencionais e do tipo "SFBR" (Seguro, Fácil, Barato e Racional). O objetivo desta revisão não é estabelecer o "estado da arte" ou diretrizes rígidas para o tratamento da DN. Diferente disso, pretendemos apenas trazer aos leitores novas possibilidades de tratamento assim como motivar pesquisadores a confirmar estes resultados preliminares, mas promissores para o alívio da DN.Palavras-chave: dor neuropática, tratamento, alternativo, medicina baseada em evidência.Neuropathic pain is defined as pain caused by lesion or dysfunction of the somatosensory system 1 and is most commonly consequence from several clinical conditions, such as diabetes, chemotherapy, herpes zoster infection, chronic alcohol abuse and other idiopathic conditions, such as idiopathic small fiber neuropathy and trigeminal pain. Patients with NP usually complain of burning and tingling sensations over the skin that almost always correspond to a plausible body distribution. Antidepressants and antiepileptic drugs are the mainstay of therapy, but they usually relieve only 40-50% of the pain 2 . Since the diagnosis of NP has becoming clearer in the last few years with the advent of new neurophysiological and histological tools, it is believed that the diversity of pathophysiological mechanism might explain the refractoriness of NP to the conventional therapeutic approaches. Therefore, several lines of investigation have been developed in parallel with the sophistication of usual drugs used in NP patients. Some of these...

show abstract

Intranasal lidocaine 8% spray for second-division trigeminal neuralgia

Abstract: Intranasal lidocaine 8% administered by a metered-dose spray produced prompt but temporary analgesia without serious adverse reactions in patients with second-division trigeminal neuralgia.

Cited by 95 publications

References 16 publications

Treatment options in trigeminal neuralgia

Treatment options in trigeminal neuralgia

Классическая Невралгия Тройничного Нерва

Promising treatments for neuropathic pain

Contact Info

Product

Resources

About